Systemic Lupus Erythematosus - Epidemiology Forecast to 2027

  • ID: 4463953
  • Report
  • 50 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
The ‘Systemic Lupus Erythematosus - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Systemic Lupus Erythematosus Epidemiology

The Systemic Lupus Erythematosus (SLE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Systemic Lupus Erythematosus are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Systemic Lupus Erythematosus Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, Lupus Nephritis prevalent cases, diagnosed cases and treatable cases) scenario of Systemic Lupus Erythematosus (SLE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to the report, the total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 5, 76,232 and 850,000 in 7MM respectively, in the year 2016.

Report Scope
  • The report covers detailed overview of Systemic Lupus Erythematosus explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Systemic Lupus Erythematosus in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender, and Clinical Manifestation i.e., Lupus Nephritis in 7MM
Key strengths
  • 10 Year Forecast of Systemic Lupus Erythematosus epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of SLE
  • Prevalent Cases according to segmentation: Gender-specific prevalence and prevalence of Clinical Manifestation i.e., Lupus Nephritis
  • Diagnosed and treatable cases of SLE
Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Systemic Lupus Erythematosus (SLE) Epidemiology Overview at a Glancye
2.1. Total Prevalent Cases of Systemic Lupus Erythematosus (SLE) - by Country (2017)
2.2. Total Market by Region of Systemic Lupus Erythematosus (SLE) (2017 & 2027)

3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)
3.1. Introduction
3.2. Risk Factors
3.3. Causes
3.4. Symptoms
3.5. Clinical Manifestations
3.6. Pathogenesis
3.7. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM
4.4. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – By Region
4.5. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2017)
4.6. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2027)

5. Epidemiology of Systemic Lupus Erythematosus (SLE)
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States
5.1.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States
5.1.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United States
5.1.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United States
5.1.6. Prevalence of Lupus Nephritis (LN) in United States
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) (AK) in Germany
5.2.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany
5.2.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany
5.2.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Germany
5.2.6. Prevalence of Lupus Nephritis (LN) in Germany
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in France
5.3.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France
5.3.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in France
5.3.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in France
5.3.6. Prevalence of Lupus Nephritis (LN) in France
5.4. Italy
5.4.1. Assumptions and Rationale
5.4.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy
5.4.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy
5.4.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy
5.4.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Italy
5.4.6. Prevalence of Lupus Nephritis (LN) in Italy
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain
5.5.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain
5.5.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain
5.5.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Spain
5.5.6. Prevalence of Lupus Nephritis (LN) in Spain
5.6. United Kingdom
5.6.1. Assumptions and Rationale
5.6.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United Kingdom
5.6.6. Prevalence of Lupus Nephritis (LN) in United Kingdom
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan
5.7.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan
5.7.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan
5.7.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Japan
5.7.6. Prevalence of Lupus Nephritis (LN) in Japan

6. Treatment Practices
6.1. Treatment Goals
6.2. Treatment Algorithm

7. Unmet Needs

8. Appendix

9. Report Methodology
9.1. Sources Used

10. Publisher Capabilities

11. Disclaimer

12. About the Publisher

List of Tables:
Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)
Table 2: THE 1982 REVISED CRITERIA FOR CLASSIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS
Table 3: Differential Diagnosis of Systemic Lupus Erythematosus
Table 4: Diagnostic Criteria for Systemic Lupus Erythematosus
Table 5: Diagnostic Tests for Systemic Lupus Erythematosus
Table 6: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027)
Table 7: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027)
Table 8: Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027)
Table 9: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027)
Table 10: Treatable Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027)
Table 11: Sex-Specific Distribution of Systemic Lupus Erythematosus (SLE) in United States (2017)
Table 12: Prevalent Population of Lupus Nephritis (LN) in United States (2016-2027)
Table 13: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Table 14: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Table 15: Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Table 16: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017)
Table 17: Prevalent Population of Lupus Nephritis (LN) in Germany (2016-2027)
Table 18: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Table 19: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Table 20: Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Table 21: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017)
Table 22: Prevalent Population of Lupus Nephritis (LN) in France (2016-2027)
Table 23: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Table 24: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Table 25: Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Table 26: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017)
Table 27: Prevalent Population of Lupus Nephritis (LN) in Italy (2016-2027)
Table 28: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Table 29: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Table 30: Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Table 31: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017)
Table 32: Prevalent Population of Lupus Nephritis (LN) in Spain (2016-2027)
Table 33: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Table 34: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Table 35: Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Table 36: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017)
Table 37: Prevalent Population of Lupus Nephritis (LN) in United Kingdom (2016-2027)
Table 38: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Table 39: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Table 40: Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Table 41: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017)
Table 42: Prevalent Population of Lupus Nephritis (LN) in Japan (2016-2027)

List of Figures:
Figure 1: Risk Factors of SLE
Figure 2: Pathogenesis of Systemic Lupus Erythematosus
Figure 3: Algorithm for diagnosis of Systemic Lupus Erythematosus
Figure 4: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027)
Figure 5: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027)
Figure 6: Prevalent Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027)
Figure 7: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027)
Figure 8:Treatable Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027)
Figure 9: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in US (2017)
Figure 10: Prevalent Population of Lupus Nephritis in United States (2016-2027)
Figure 11: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Figure 12: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Figure 13:Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027)
Figure 14: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017)
Figure 15: Prevalent Population of Lupus Nephritis in Germany (2016-2027)
Figure 16: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Figure 17: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Figure 18:Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027)
Figure 19: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017)
Figure 20: Prevalent Population of Lupus Nephritis in France (2016-2027)
Figure 21: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Figure 22: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Figure 23:Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027)
Figure 24: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017)
Figure 25: Prevalent Population of Lupus Nephritis in Italy (2016-2027)
Figure 26: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Figure 27: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Figure 28:Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027)
Figure 29: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017)
Figure 30: Prevalent Population of Lupus Nephritis in Spain (2016-2027)
Figure 31: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Figure 32: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Figure 33:Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027)
Figure 34: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017)
Figure 35: Prevalent Population of Lupus Nephritis in United Kingdom (2016-2027)
Figure 36: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Figure 37: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Figure 38:Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027)
Figure 39: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017)
Figure 40: Prevalent Population of Lupus Nephritis in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll